APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Malaria

Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.

Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Malaria Market Outlook and Growth Opportunities 2026

2 January 2026194 pages

Choose your research edition.

Industry ResearchDrugs for Malaria Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Malaria Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Drugs for Malaria Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Malaria Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Malaria Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.

Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.

In the U.S. market, the major manufacturers are Cipla, Guilin Southern Medicine, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aentis and Ajanta Pharma, etc, with about 73% market shares.

Read the full market overview

This report provides an overview of the global Drugs for Malaria market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Malaria and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Malaria revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs for Malaria market.

Drugs for Malaria Segment by Company

Cipla

Guilin Pharmaceutical

IPCA Laboratories

GlaxoSmithKline

Mylan Labs

Roche

Novartis

Sanofi Aventis

Ajanta Pharma

Drugs for Malaria Segment by Type

Aryl Aminoalcohol Compounds

Antifolate Compounds

Artemisinin Compounds

Drugs for Malaria Segment by Application

Prevention

Treatment

Others

Drugs for Malaria Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Malaria status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs for Malaria key companies, revenue, market share, and recent developments.

3. To split the Drugs for Malaria breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs for Malaria market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Malaria significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Malaria competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Malaria market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Malaria and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Malaria.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Malaria industry.

Chapter 3: Detailed analysis of Drugs for Malaria company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs for Malaria in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs for Malaria in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Malaria Industry Trends Table 2. Drugs for Malaria Industry Drivers Table 3. Drugs for Malaria Industry Opportunities and Challenges Table 4. Drugs for Malaria Industry Restraints Table 5. Global Drugs for Malaria Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Malaria Revenue Share by Company (2021-2026) Table 7. Global Drugs for Malaria Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs for Malaria Key Company Manufacturing Base & Headquarters Table 9. Global Drugs for Malaria Company, Product Type & Application Table 10. Global Drugs for Malaria Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs for Malaria by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Aryl Aminoalcohol Compounds Table 15. Significant Companies of Antifolate Compounds Table 16. Significant Companies of Artemisinin Compounds Table 17. Global Drugs for Malaria Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Drugs for Malaria Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Drugs for Malaria Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Drugs for Malaria Sales Value Share by Type (2021-2026) Table 21. Global Drugs for Malaria Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Prevention Table 23. Significant Companies of Treatment Table 24. Significant Companies of Others Table 25. Global Drugs for Malaria Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs for Malaria Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Drugs for Malaria Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Drugs for Malaria Sales Value Share by Application (2021-2026) Table 29. Global Drugs for Malaria Sales Value Share by Application (2027-2032) Table 30. Global Drugs for Malaria Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drugs for Malaria Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Drugs for Malaria Sales Value Share by Region (2021-2026) Table 33. Global Drugs for Malaria Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Drugs for Malaria Sales Value Share by Region (2027-2032) Table 35. Global Drugs for Malaria Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drugs for Malaria Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Drugs for Malaria Sales Value Market Share by Country (2021-2026) Table 38. Global Drugs for Malaria Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Drugs for Malaria Sales Value Market Share by Country (2027-2032) Table 40. Cipla Company Information Table 41. Cipla Business Overview Table 42. Cipla Drugs for Malaria Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Cipla Drugs for Malaria Product Portfolio Table 44. Cipla Recent Development Table 45. Guilin Pharmaceutical Company Information Table 46. Guilin Pharmaceutical Business Overview Table 47. Guilin Pharmaceutical Drugs for Malaria Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Guilin Pharmaceutical Drugs for Malaria Product Portfolio Table 49. Guilin Pharmaceutical Recent Development Table 50. IPCA Laboratories Company Information Table 51. IPCA Laboratories Business Overview Table 52. IPCA Laboratories Drugs for Malaria Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. IPCA Laboratories Drugs for Malaria Product Portfolio Table 54. IPCA Laboratories Recent Development Table 55. GlaxoSmithKline Company Information Table 56. GlaxoSmithKline Business Overview Table 57. GlaxoSmithKline Drugs for Malaria Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. GlaxoSmithKline Drugs for Malaria Product Portfolio Table 59. GlaxoSmithKline Recent Development Table 60. Mylan Labs Company Information Table 61. Mylan Labs Business Overview Table 62. Mylan Labs Drugs for Malaria Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Mylan Labs Drugs for Malaria Product Portfolio Table 64. Mylan Labs Recent Development Table 65. Roche Company Information Table 66. Roche Business Overview Table 67. Roche Drugs for Malaria Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Roche Drugs for Malaria Product Portfolio Table 69. Roche Recent Development Table 70. Novartis Company Information Table 71. Novartis Business Overview Table 72. Novartis Drugs for Malaria Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Novartis Drugs for Malaria Product Portfolio Table 74. Novartis Recent Development Table 75. Sanofi Aventis Company Information Table 76. Sanofi Aventis Business Overview Table 77. Sanofi Aventis Drugs for Malaria Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sanofi Aventis Drugs for Malaria Product Portfolio Table 79. Sanofi Aventis Recent Development Table 80. Ajanta Pharma Company Information Table 81. Ajanta Pharma Business Overview Table 82. Ajanta Pharma Drugs for Malaria Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Ajanta Pharma Drugs for Malaria Product Portfolio Table 84. Ajanta Pharma Recent Development Table 85. Research Programs/Design for This Report Table 86. Authors List of This Report Table 87. Secondary Sources Table 88. Primary Sources List of Figures Figure 1. Drugs for Malaria Product Image Figure 2. Global Drugs for Malaria Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Malaria Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Malaria Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Aryl Aminoalcohol Compounds Image Figure 8. Antifolate Compounds Image Figure 9. Artemisinin Compounds Image Figure 10. Global Drugs for Malaria Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Drugs for Malaria Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs for Malaria Sales Value Share by Type (2021-2032) Figure 13. Prevention Image Figure 14. Treatment Image Figure 15. Others Image Figure 16. Global Drugs for Malaria Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drugs for Malaria Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Drugs for Malaria Sales Value Share by Application (2021-2032) Figure 19. Global Drugs for Malaria Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Drugs for Malaria Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Drugs for Malaria Sales Value (2021-2032) & (US$ Million) Figure 22. North America Drugs for Malaria Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Drugs for Malaria Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Drugs for Malaria Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Drugs for Malaria Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Drugs for Malaria Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Drugs for Malaria Sales Value (2021-2032) & (US$ Million) Figure 28. South America Drugs for Malaria Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Drugs for Malaria Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Drugs for Malaria Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Drugs for Malaria Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Drugs for Malaria Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Drugs for Malaria Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Aryl Aminoalcohol Compounds
  • Antifolate Compounds
  • Artemisinin Compounds
Applications
  • Prevention
  • Treatment
  • Others
Companies covered
  • Cipla
  • Guilin Pharmaceutical
  • IPCA Laboratories
  • GlaxoSmithKline
  • Mylan Labs
  • Roche
  • Novartis
  • Sanofi Aventis
  • Ajanta Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Malaria Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Malaria Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs for Malaria Market Dynamics
  1. 2.1 Drugs for Malaria Industry Trends
  2. 2.2 Drugs for Malaria Industry Drivers
  3. 2.3 Drugs for Malaria Industry Opportunities and Challenges
  4. 2.4 Drugs for Malaria Industry Restraints
3 Drugs for Malaria Market by Company
  1. 3.1 Global Drugs for Malaria Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Malaria Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Malaria Company Ranking (2024-2026)
  4. 3.4 Global Drugs for Malaria Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs for Malaria Company Product Type and Application
  6. 3.6 Global Drugs for Malaria Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs for Malaria Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs for Malaria Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs for Malaria Market by Type
  1. 4.1 Drugs for Malaria Type Introduction
  2. 4.1.1 Aryl Aminoalcohol Compounds
  3. 4.1.2 Antifolate Compounds
  4. 4.1.3 Artemisinin Compounds
  5. 4.2 Global Drugs for Malaria Sales Value by Type
  6. 4.2.1 Global Drugs for Malaria Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Malaria Sales Value by Type (2021-2032)
  8. 4.2.3 Global Drugs for Malaria Sales Value Share by Type (2021-2032)
5 Drugs for Malaria Market by Application
  1. 5.1 Drugs for Malaria Application Introduction
  2. 5.1.1 Prevention
  3. 5.1.2 Treatment
  4. 5.1.3 Others
  5. 5.2 Global Drugs for Malaria Sales Value by Application
  6. 5.2.1 Global Drugs for Malaria Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Malaria Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drugs for Malaria Sales Value Share by Application (2021-2032)
6 Drugs for Malaria Regional Value Analysis
  1. 6.1 Global Drugs for Malaria Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Malaria Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs for Malaria Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs for Malaria Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Malaria Sales Value (2021-2032)
  7. 6.3.2 North America Drugs for Malaria Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs for Malaria Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs for Malaria Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs for Malaria Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs for Malaria Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs for Malaria Sales Value (2021-2032)
  16. 6.6.2 South America Drugs for Malaria Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs for Malaria Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs for Malaria Sales Value Share by Country, 2025 VS 2032
7 Drugs for Malaria Country-level Value Analysis
  1. 7.1 Global Drugs for Malaria Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Malaria Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs for Malaria Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs for Malaria Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs for Malaria Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs for Malaria Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs for Malaria Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs for Malaria Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs for Malaria Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs for Malaria Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs for Malaria Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs for Malaria Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs for Malaria Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs for Malaria Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs for Malaria Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs for Malaria Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs for Malaria Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs for Malaria Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs for Malaria Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs for Malaria Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs for Malaria Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs for Malaria Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs for Malaria Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs for Malaria Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs for Malaria Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs for Malaria Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs for Malaria Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs for Malaria Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs for Malaria Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs for Malaria Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs for Malaria Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs for Malaria Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs for Malaria Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs for Malaria Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cipla
  2. 8.1.1 Cipla Company Information
  3. 8.1.2 Cipla Business Overview
  4. 8.1.3 Cipla Drugs for Malaria Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cipla Drugs for Malaria Product Portfolio
  6. 8.1.5 Cipla Recent Developments
  7. 8.2 Guilin Pharmaceutical
  8. 8.2.1 Guilin Pharmaceutical Company Information
  9. 8.2.2 Guilin Pharmaceutical Business Overview
  10. 8.2.3 Guilin Pharmaceutical Drugs for Malaria Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Guilin Pharmaceutical Drugs for Malaria Product Portfolio
  12. 8.2.5 Guilin Pharmaceutical Recent Developments
  13. 8.3 IPCA Laboratories
  14. 8.3.1 IPCA Laboratories Company Information
  15. 8.3.2 IPCA Laboratories Business Overview
  16. 8.3.3 IPCA Laboratories Drugs for Malaria Revenue and Gross Margin (2021-2026)
  17. 8.3.4 IPCA Laboratories Drugs for Malaria Product Portfolio
  18. 8.3.5 IPCA Laboratories Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Drugs for Malaria Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Drugs for Malaria Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 Mylan Labs
  26. 8.5.1 Mylan Labs Company Information
  27. 8.5.2 Mylan Labs Business Overview
  28. 8.5.3 Mylan Labs Drugs for Malaria Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Labs Drugs for Malaria Product Portfolio
  30. 8.5.5 Mylan Labs Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Drugs for Malaria Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Drugs for Malaria Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Drugs for Malaria Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Drugs for Malaria Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Sanofi Aventis
  44. 8.8.1 Sanofi Aventis Company Information
  45. 8.8.2 Sanofi Aventis Business Overview
  46. 8.8.3 Sanofi Aventis Drugs for Malaria Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Aventis Drugs for Malaria Product Portfolio
  48. 8.8.5 Sanofi Aventis Recent Developments
  49. 8.9 Ajanta Pharma
  50. 8.9.1 Ajanta Pharma Company Information
  51. 8.9.2 Ajanta Pharma Business Overview
  52. 8.9.3 Ajanta Pharma Drugs for Malaria Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ajanta Pharma Drugs for Malaria Product Portfolio
  54. 8.9.5 Ajanta Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst